Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398

Cancer Research

Volumn 58, Issue 23, 1998, Pages 5354-5360

  Rioux, Nathalie ^a   Castonguay, Andre ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG STABILITY; EXPERIMENTAL NEOPLASM; FEMALE; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH INJURY;

ANIMALS; ANTICARCINOGENIC AGENTS; ASPIRIN; BIOTRANSFORMATION; CARCINOGENS; CELL DIVISION; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG STABILITY; FEMALE; HYDROXYLATION; ISOENZYMES; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MICE, INBRED A; NITROBENZENES; NITROSAMINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES;

EID: 0032403140     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. IARC. Handbooks of Cancer Prevention. Nonsteroidal Anti-inflammatory Drugs. IARC Sci. Publ., 1: 15-39, 1997.
2. Marnett, L. J. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res., 52: 5575-5589, 1992.
3. Harris, R. E., Namboodiri, K. K., and Farrar, W. B. Nonsteroidal anti-inflammatory drugs and breast cancer. Epidemiology, 7: 203-205, 1996.
4. Thun, M., Namboodiri, M., Calle, E., Flanders, W., and Heath, C. Aspirin use and risk of fatal cancer. Cancer Res., 53: 1322-1327, 1993.
5. Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., and Willett, W. C. Aspirin use and risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 121: 241-246, 1994.
6. Duperron, C., and Castonguay, A. Chemoprevention efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis (Lond.), 18: 1001-1006, 1997.
7. Trujillo, M. A., Garewal, H. S., and Sampliner, R. E. Nonsteroidal anti-inflammatory agents in chemoprevention of colorectal cancer. At what cost? Dig. Dis. Sci., 39: 2260-2266, 1994.
8. Gabriel, S. E., Jaakkimainon, L., and Bombardier, C. Risk for serious gastrointestinal complication related to use of nonsteroidal anti-inflammatory drugs. Ann. Intern. Med., 115: 787-796, 1991.
9. Clive, D. M., and Stoff, J. S. Renal syndromes associated with non-steroidal anti-inflammatory drugs. N. Engl. J. Med., 310: 563-572, 1984.
10. Whittle, B. J. R., Higgs, G. A., Eakins, K. E., Moncada, S., and Vane, J. R. Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature (Lond.), 284: 271-273, 1980.
11. O'Bannion, M. K., Winn, V. D., and Yung, D. A. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA, 89: 4888-4892, 1992.
12. Hempel, S. L., Monik, M. M., and Hunnighake, G. W. Lipopolysaccharide induces prostaglandin H synthase-2 protein and mRNA in human alveolar macrophages and blood monocytes. J. Clin. Invest., 93: 391-396, 1994.
13. Eberhart, G. E., Coffey, R. J., Radhika, A., Giardello, F. M., Ferrenbach, S., and DuBois, R. N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107: 1183-1188, 1994.
14. 2 and cyclooxygenase, in the large bowel mucosa and neoplasms of F344 rats treated with naturally occuring carcinogen, 1-hydroxyanthraquinone. Cancer Lett., 97: 75-82, 1995.
15. Sano, H., Kawahito, Y., Wilder, R. L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., and Hla, T. Expression of cyclooxygenase-1 and -2 in human colorecta) cancer. Cancer Res., 55: 3785-3789, 1995.
16. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
17. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
18. Jones, D. A., Carlton, D. P., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J. Biol. Chem., 268: 9049-9054, 1993.
19. Vane, J. R. Towards a better aspirin. Nature (Lond.), 367: 215-216, 1994.
20. Arai, I., Hamasaka, Y., Futaki, N., Takahashi, S., Yoshikawa, K., Higuchi, S., and Otomo, S. Effect of NS-398, a new nonsteroidal anti-inflammatory agent, on gastric ulceration and acid secretion in rats. Res. Commun. Chem. Pathol. Pharmacol., 81: 259-270, 1993.
21. Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H., and Otomo, S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen. Pharmacol., 24: 105-110, 1993.
22. Copeland, R. A., Williams, J. M., Giannaras, J., Nurnberg, S., Covington, M., Pinto, D., Pick, S., and Trzaskos, J. M. Mechanism of selective inhibition of the inducible form of prostaglandin G/H synthase. Proc. Natl. Acad. Sci. USA, 91: 11202-11206, 1994.
23. Kawabata, K., Yoshimi, N., Hirose, Y., Hara, A., and Mori, H. Reduction of azoxymethane-induced aberrant crypt foci by a selective cyclooxygenase-2 inhibitor, NS-398 in F344 rats. Proc. Am. Assoc. Cancer Res., 38: 210, 1997.
24. Pretlow, T. P., O'Riordan, M. A., Pretlow, T. G., and Stellato, T. A. Aberrant crypts in human colonie mucosa: putative preneoplastic lesions. J. Cell. Biochem., 16G: 55X-62X, 1992.
25. Peleg, I.I., Maibach, H. T., Brown, S. H., and Wilcox, C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch. Intern. Med., 154: 394-399, 1994.
26. Evans, W. K., Will, B. P., Berthelot, J-M., and Wolfson, M. C. The cost of managing lung cancer in Canada. Oncology, 9: 147-153, 1995.
27. Hoffmann, D., Rivenson, A., and Hecht, S. S. The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Crit. Rev. Toxicol., 26: 199-211, 1996.
28. Hecht, S. S. Metabolic activation and detoxification of tobacco-specific nitrosamines - a model for cancer prevention strategies. Drug Metab. Rev., 26: 373-390, 1994.
29. Marnett, L. J., Reed, G. A., and Dennison, D. J. Prostaglandin synthetase dependent activation of 7,8-dihydroxy-benzo(a)pyrene to mutagenic derivatives. Biochem. Biopys. Res. Commun., 82: 210-216, 1978.
30. Robertson, I. G. C., Sivarajah, K., Eling, T. E., and Zeiger, E. Activation of some aromatic amines to mutagenic products by prostaglandin endoperoxide synthase. Cancer Res., 41: 476-480, 1983.
31. Sarkar, F. H., Radcliff, G., Callewaert, D. M., Marnett, L. J., Eling, T., Daston, D. S., and Caspary, W. J. Mutagenic response of mouse lymphoma cells after activation of benzidine and 2-aminofluorene with purified prostaglandin H synthase. Mutat. Res., 242: 319-328, 1990.
32. Hecht, S. S., Young, R., and Chen, C. B. Metabolism in the F344 rat of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific carcinogen. Cancer Res., 40: 4144-4150, 1980.
33. Rioux, N., and Castonguay, A. Recovery from 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induce immunosuppression in A/J mice by treatment with nonsteroidal anti-inflammatory drugs. J. Natl. Cancer Inst., 89: 874-880, 1997.
34. Powell, W. S. Rapid extraction of arachidonic acid metabolites from biological samples using octadecylsilyl silica. Methods Enzymol., 86: 467-477, 1982.
35. Pradelles, P., Grassi, J., and Maclowf, J. Enzyme immunoassays of eicosanoids using acetylcholinesterase. Methods Enzymol., 187: 24-34, 1990.
36. Jorquera, R., Castonguay, A., and Schuller, H. M. Effects of pregnancy and ethanol treatment on the metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone by hamster liver and lung microsomes. Drug Metab. Dispos., 20: 510-517, 1992.
37. Lowry, O. H., Rosenbrough, N. J., Fair, L., and Randall, R. J. Protein measurements with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
38. Smith, T. J., Guo, Z., Thomas, P. E., Chung, F-L., Morse, M. A., Elkind, K., and Yang, C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in mouse lung microsomes and its inhibition by isothiocyanates. Cancer Res., 50: 6817-6822, 1990.
39. Castonguay, A., Lin, D., Stoner, G. D., Radok, P., Furaya, S. S., Hecht, S. S., Schut, A. G., and Klauning, J. E. Comparative carcinogenecity in A/J mice and metabolism by cultured mouse peripheral lung of N′-nitrosonornicotine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and their analogues. Cancer Res., 43: 1223-1229, 1983.
40. Pan, Y. H. L., Nuzum, E., Hanson, L. A., and Beer, D. G. Ki-ras activation and expression in transformed mouse lung cell lines. Mol. Carcinog., 3: 279-286, 1990.
41. Hansen, M. B., Nielson, S. E., and Berg, K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Methods, 119: 203-210, 1989.
42. Castonguay, A., and Rioux, N. Inhibition of lung tumourigenesis by sulindac: comparison of two experimental protocols. Carcinogenesis (Lond.), 18: 491-496, 1997.
43. Liu, N., and Rose, D. P. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res., 56: 5125-5127, 1996.
44. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D., and DuBois, R. N. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111: 1134-1140, 1996.
45. Subbaramaiah, K., Telang, N., Ramonetti, J. T., Araki, R., DeVito, B., Weksler, B. B., and Dannenberg, A. J. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res., 56: 4424-4429.
46. Lanza, F. L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal anti-inflammatory drugs. Scand. J. Gastroenterol., 24: 24-31, 1989.
47. Cay, Y., Appelkvist, E-L., and DePierre, M. Hepatic oxidatives stress and related deferences during treatment of mice with acetylsalicylic acid and other peroxisome proliferators. J. Biochem. Toxicol., 10: 87-94, 1995.
48. Hixson, L. J., Alberts, D. S., Krutzsch, M., Einsphar, J., Brendel, K., Gross, P. H., Paranka, N. S., Baier, M., Emerson, S., Pamukcu, R., and Burt, R. W. Antiproliferative effect of nonsteroidal anti-inflammatory drugs against human colon cancer cells. Cancer Epidemiol. Biomark. Prev., 3: 433-438, 1994.
49. Miyamoto, T., Ogino, N., Yamamoto, S., and Hayaishi, O. Purification of prostaglandin endoperoxide synthase from bovine vesicular gland microsomes. J. Biol. Chem., 251: 2629-2636, 1976.
50. Mizuno, K., Yamamoto, S., and Lands, W. E. M. Effects of non-steroidal anti-inflammatory drugs on fatty acid cyclooxygenase and prostaglandin hydroperoxidase activities. Prostaglandins, 23: 743-757, 1982.
51. Yao, R., Rioux, N., Castonguay, A., and You, M. Inhibition of COX-2 and induction of apoptosis: two determinants of NSAIDs chemopreventive efficacies in mouse lung tumorigenesis. Proc. Am. Assoc. Cancer Res., 39: 195, 1998.
52. Martin, U., and Prescott, L. F. The interaction of paracetamol with frusamide. Br. J. Clin. Pharmacol., 37: 464-467, 1994.
53. Clissold, S. P. Paracetamol and phenacetin. Drugs, 32: 46-59, 1986.
54. 2+ accumulation and early DNA fragmentation with cell death. Toxicol. Appl. Pharmacol., 111: 242-254, 1991.